Stock listing

NASDAQ:ALLO Allogene Therapeutics, Inc. Stock

Home listing (NASDAQ) of Allogene Therapeutics, Inc.

Follow Allogene Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ALLO

$0.628 USD -0.068 (-9.8%)

Close on Nov 20, 2026

Past year -49.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.619 – $0.670 USDNov 20, 2026
Volume
7.58M sharesNov 20, 2026
Market cap
$217.5M USDAt the close on Nov 20, 2026 · price × 346.5M shares outstanding
52-week range
$0.619 – $4.460 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$10.27M USDMedian day 5.99M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Allogene Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ALLO · Home$0.628 USD-0.068 (-9.8%)7,578,372$0.642$0.670$0.619$0.696Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALLO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.628-0.068-9.8%$0.642$0.670$0.6197,578,372
$0.696-0.048-6.5%$0.760$0.776$0.68610,550,720
$0.744-0.063-7.8%$0.800$0.815$0.7408,487,651
$0.807-0.032-3.8%$0.838$0.850$0.7678,706,303
$0.839+0.012+1.4%$0.839$0.865$0.82011,604,145
$0.827-0.073-8.1%$0.890$0.897$0.82210,627,936
$0.900-0.032-3.4%$0.955$0.960$0.88015,359,219
$0.932-0.128-12.1%$1.040$1.040$0.89022,863,434
$1.060+0.020+1.9%$1.100$1.100$1.00010,731,720
$1.040-0.050-4.6%$1.090$1.130$0.98012,560,973
$1.090-0.100-8.4%$1.180$1.190$1.05015,284,769
$1.190+0.070+6.2%$1.160$1.200$1.12016,527,072
$1.120+0.030+2.8%$1.120$1.140$1.10017,665,305
$1.090-0.090-7.6%$1.230$1.230$1.07010,058,285
$1.180-0.070-5.6%$1.240$1.258$1.1609,758,925
$1.250-0.050-3.8%$1.330$1.380$1.2507,714,051
$1.300+0.070+5.7%$1.220$1.335$1.21010,323,337
$1.230+0.020+1.7%$1.210$1.260$1.17016,102,778
$1.210-0.040-3.2%$1.260$1.270$1.19010,576,283
$1.2500.0000.0%$1.230$1.255$1.1608,404,820
$1.250-0.080-6.0%$1.320$1.330$1.2208,296,399
$1.3300.0000.0%$1.330$1.365$1.3104,742,434
$1.330+0.030+2.3%$1.300$1.350$1.2904,579,577
$1.300-0.010-0.8%$1.300$1.330$1.2605,906,271
$1.310-0.030-2.2%$1.340$1.340$1.2904,919,065
$1.340+0.040+3.1%$1.330$1.370$1.3004,515,192
$1.300+0.010+0.8%$1.280$1.308$1.2207,736,868
$1.290-0.110-7.9%$1.390$1.395$1.2906,543,528
$1.400-0.060-4.1%$1.450$1.460$1.3904,316,472
$1.460+0.060+4.3%$1.390$1.480$1.37010,605,410
$1.400-0.030-2.1%$1.440$1.440$1.3457,983,952
$1.430-0.030-2.1%$1.460$1.470$1.4203,899,722
$1.460-0.040-2.7%$1.500$1.500$1.4304,659,678
$1.5000.0000.0%$1.495$1.520$1.4504,443,265
$1.500-0.040-2.6%$1.570$1.579$1.5004,656,621
$1.540-0.060-3.8%$1.600$1.610$1.5304,606,898
$1.600-0.020-1.2%$1.610$1.660$1.5808,132,422
$1.620-0.010-0.6%$1.600$1.645$1.6004,318,917
$1.630-0.020-1.2%$1.650$1.665$1.6005,026,155
$1.650-0.020-1.2%$1.690$1.695$1.6303,622,349
$1.6700.0000.0%$1.670$1.720$1.6007,791,092
$1.670-0.040-2.3%$1.730$1.740$1.6505,965,945
$1.710+0.020+1.2%$1.720$1.740$1.6835,237,474
$1.6900.0000.0%$1.710$1.720$1.6455,992,401
$1.690-0.040-2.3%$1.730$1.740$1.67012,716,960
$1.730+0.040+2.4%$1.740$1.765$1.7003,948,057
$1.690-0.030-1.7%$1.740$1.770$1.6605,648,084
$1.720-0.060-3.4%$1.800$1.800$1.7103,138,618
$1.7800.0000.0%$1.775$1.840$1.7657,750,773
$1.780+0.020+1.1%$1.800$1.805$1.7543,894,350
$1.760+0.030+1.7%$1.730$1.780$1.6955,401,051
$1.730-0.130-7.0%$1.850$1.875$1.7207,284,015
$1.860-0.110-5.6%$1.930$1.940$1.8507,434,268
$1.970-0.010-0.5%$1.970$2.010$1.9504,428,567
$1.9800.0000.0%$2.000$2.010$1.9204,425,096
$1.980-0.005-0.3%$1.970$2.040$1.9105,393,709
$1.985-0.015-0.7%$1.960$1.999$1.9304,037,910
$2.000-0.020-1.0%$2.010$2.020$1.9554,376,900
$2.020-0.070-3.3%$2.080$2.090$2.0003,824,689
$2.090+0.050+2.5%$2.040$2.140$2.0004,982,882
$2.040-0.130-6.0%$2.170$2.180$2.0305,020,715
$2.170+0.140+6.9%$2.050$2.210$2.0506,156,769
$2.030-0.060-2.9%$2.110$2.110$2.0004,755,951
$2.090-0.010-0.5%$2.120$2.150$2.0604,372,792
$2.100-0.130-5.8%$2.190$2.210$2.0704,861,236
Ticker
NASDAQ:ALLO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Allogene Therapeutics, Inc. news

Allogene Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 186 in all · newest Nov 20, 2026 · oldest 2019
Calls
27 calls with a replay · 27 with a transcript · latest Nov 5, 2026
Decks
12 decks · latest Aug 12, 2026

Where Allogene Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ALLO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ALLOBOATSUnited StatesUSD

Valuation

EV/sales −1.6× against a median of 99.4×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$7.44M USD
P/E
Loss
EV/sales
−1.6×
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.2×
Beta vs S&P 500
1.93

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Allogene Therapeutics, Inc. · NASDAQ:ALLOUS$217.5M−US$7.44Mn/a−1.6×n/a0.6×n/a0.2×1.93
Aprilbio Co., Ltd. · KRX:397030US$222.4MUS$162.1Mn/an/an/a3.1×n/a0.0×n/a
Enanta Pharmaceuticals, Inc. · NASDAQ:ENTAUS$222.2MUS$82.43Mn/a1.3×n/a2.8×−108.3%0.7×1.11
Clover Biopharmaceuticals Ltd. · HKEX:2197US$222.0MUS$206.6Mn/a404×n/an/an/an/an/a
Northwest Biotherapeutics, Inc. · OTC:NWBOUS$220.0MUS$283.8Mn/a99.4×n/an/an/an/a0.90
Keros Therapeutics, Inc. · NASDAQ:KROSUS$219.7M−US$24.67Mn/a−0.6×n/a0.8×−152.7%0.1×1.16
Immuneering Corporation · NASDAQ:IMRXUS$218.7MUS$160.5Mn/an/an/a1.3×n/a0.0×1.17
ProKidney Corp. · NASDAQ:PROKUS$217.3MUS$77.56Mn/a100×n/an/an/an/a1.61
Pyxis Oncology, Inc. · NASDAQ:PYXSUS$216.5MUS$160.9Mn/an/an/a5.2×n/a0.0×0.89
Oryzon Genomics SA · BME:ORYUS$216.4MUS$206.7Mn/an/an/a1.6×n/a0.1×n/a
Rocket Pharmaceuticals, Inc. · NASDAQ:RCKTUS$214.1M−US$25.02Mn/an/an/a0.7×n/a0.1×1.72
Median of the othersUS$219.2MUS$160.7M99.4×1.6×−130.5%0.1×1.16

Forecasts

8 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
9.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.58 · 6 analysts
Revenue, year to Dec 2026
3.78M · 11 analysts

Team and board

Officers

OfficerRole
Liz BarrettPresident and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology
Zachary RobertsPresident and Chief Executive Officer
Earl DouglasGeneral Counsel
Leslie BryantExecutive Director, Corporate Communications
Annie YoshiyamaSenior Vice President, Finance and Corporate Controller, and Principal Accounting Officer
Benjamin M. BeneskiSenior Vice President, Chief Technical Officer
Christine CassianoExecutive Vice President, Chief Corporate Affairs and Brand Strategy Officer
Geoffrey ParkerExecutive Vice President
Rocio ManghaniVice President, Market Access, Evidence & Strategy
Allogene Media/Investor Contact:Christine CassianoEVPChief Corporate Affairs & Brand Strategy
Arie BelldegrunExecutive Chairman and Co-Founder
David ChangCo-Founder
Joshua KazamCo-Founder and Director
Susie LundeenChief People Officer

Board

DirectorRole
Arie BelldegrunExecutive Chairman and Co-Founder
David ChangCo-Founder
Franz B. HumerLead Independent Director
Joshua KazamCo-Founder and Director
Leslie BryantExecutive Director, Corporate Communications
Liz BarrettPresident and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology
Owen WitteProfessor of Microbiology, Immunology and Molecular Genetics
Stephen MayoBren Professor of Biology and Chemistry and Merkin Institute Professor
Vicki SatoDirector
Zachary RobertsPresident and Chief Executive Officer

Events

Calls

CallWhenStatus
Allogene Therapeutics (NASDAQ:ALLO) Q3 2026 Earnings CallThu, Nov 05, 2026 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q2 2026 Earnings CallWed, Aug 12, 2026 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q1 2026 Earnings CallWed, May 13, 2026 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q4 2025 Earnings CallThu, Mar 12, 2026 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q3 2025 Earnings CallThu, Nov 06, 2025 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q2 2025 Earnings CallWed, Aug 13, 2025 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q1 2025 Earnings CallTue, May 13, 2025 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q4 2024 Earnings CallThu, Mar 13, 2025 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q3 2024 Earnings CallThu, Nov 07, 2024 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q2 2024 Earnings CallWed, Aug 07, 2024 · 5:00 PM ETReplay
All 27 calls
CallWhenStatus
Allogene Therapeutics (NASDAQ:ALLO) Q1 2024 Earnings CallMon, May 13, 2024 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q4 2023 Earnings CallThu, Mar 14, 2024 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q3 2023 Earnings CallThu, Nov 02, 2023 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q2 2023 Earnings CallWed, Aug 02, 2023 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q1 2023 Earnings CallWed, May 03, 2023 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q4 2022 Earnings CallTue, Feb 28, 2023 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q3 2022 Earnings CallWed, Nov 02, 2022 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q2 2022 Earnings CallTue, Aug 09, 2022 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q1 2022 Earnings CallWed, May 04, 2022 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q4 2021 Earnings CallWed, Feb 23, 2022 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q3 2021 Earnings CallThu, Nov 04, 2021 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q2 2021 Earnings CallWed, Aug 04, 2021 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q1 2021 Earnings CallWed, May 05, 2021 · 5:00 PM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q4 2020 Earnings CallThu, Feb 25, 2021 · 8:30 AM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q3 2020 Earnings CallWed, Nov 04, 2020 · 8:30 AM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q2 2020 Earnings CallWed, Aug 05, 2020 · 8:30 AM ETReplay
Allogene Therapeutics (NASDAQ:ALLO) Q1 2020 Earnings CallWed, May 06, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close−4.6%
Q2 2026Aug 12, 2026 · After close−4.3%
Q1 2026May 13, 2026 · After close−8.2%
Q4 2025Mar 4, 2026−8.7%
Q3 2025Nov 6, 2025 · After close+12.4%
Q2 2025Aug 13, 2025 · After close+2.9%
Q1 2025May 13, 2025 · After close−15.7%
Q4 2024Mar 12, 2025 · Before open+1.5%
Q3 2024Nov 7, 2024 · After close−3.5%
Q2 2024Aug 7, 2024 · After close−4.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · After close+2.1%
Q4 2023Mar 14, 2024 · After close+3.7%
Q3 2023Nov 2, 2023 · After close+17.9%
Q2 2023Aug 2, 2023 · After close+9.6%
Q1 2023May 3, 2023 · After close+12.8%
Q4 2022Feb 28, 2023 · After close−0.2%
Q3 2022Nov 2, 2022 · After close−6.4%
Q2 2022Aug 9, 2022 · After close+7.8%
Q1 2022May 4, 2022 · After close−1.9%
Q4 2021Feb 23, 2022 · After close+0.9%

Open Events

Decks

DeckKindSlidesDate
Q2 2026 Earnings PresentationEarnings36 slidesAug 12, 2026
Q4 2025 Earnings PresentationEarnings26 slidesMar 12, 2026
Fact Sheet (September 2025)Fact sheet2 slidesSeptember 2025
ASCO 2025Conference16 slidesJune 2025
Q1 2025 Earnings PresentationEarnings31 slidesMay 13, 2025
J.P. Morgan Healthcare Conference 2024Conference30 slides2024
Technical Presentation (June 2023)Technical5 slidesJune 2023
ICML 2023Conference13 slidesJune 2023
AACR Annual Meeting 2023Conference14 slidesApril 2023
Technical Presentation (2023)Technical5 slides2023
All 12 decks
DeckKindSlidesDate
Technical Presentation (December 2022)Technical9 slidesDec 1, 2022
Technical Presentation (December 2018)Technical15 slidesDecember 2018

Open Decks

Financings

RaiseDate
Public offering of common stock
Update: US$175M · US$2 a share · Goldman Sachs & Co. LLC +7
Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Piper Sandler (co-lead), William Blair (co-lead), TPG Capital BD, LLC, Baird, Canaccord Genuity
Use of proceeds: General corporate purposes, which may include clinical trial, R&D, G&A expenses and capital expenditures
Apr 14, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Oct 10, 2018.

Price
US$18.00 a share
Shares offered
18,000,000 shares of common stock
Offering size
US$324 million
Underwriters' option
Up to 2,700,000 more shares
Underwriters
Goldman Sachs & Co. LLC, J.P. Morgan, Cowen, Jefferies · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 10, 2018
Filed publiclySep 14, 2018
Amended 3 timesNewest Oct 5, 2018
Shares registered with an exchangeOct 5, 2018
Declared effective by the SECOct 10, 2018
Final prospectus, with the priceOct 11, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Oct 11, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue022.0K95.0K156.0K114.1M0000
Cost of revenue12.4M13.6M14.2M16.7M13.1M11.5M5.03M1.50M0
Gross profit-12.4M22.0K95.0K243.0K38.5M-11.5M-5.03M-1.50M0
Research and development150.2M192.3M242.9M256.4M220.2M193.0M144.5M151.9M151.9M
Selling, general and administrative56.8M65.2M71.7M79.3M74.1M65.3M57.5M41.0M24.0K
Operating income-209.3M-273.2M-327.7M-335.5M-180.2M-258.2M-202.0M-192.8M-2.00K
Depreciation and amortization12.4M13.6M14.2M14.3M10.5M7.40M4.60M1.00M24.0K
EBITDA-197.0M-259.6M-313.5M-321.2M-169.7M-250.8M-197.4M-191.8M22.0K
Interest expense1.07M181.0K017.1M10.5M003.36M0
Income before tax-190.9M-257.1M-327.3M-332.6M-257.0M-250.2M-184.9M-211.6M-24.0K
Income tax0443.0K0000-331.0K-117.0K-24.0K
Net income-190.9M-257.6M-327.3M-340.4M-182.1M-316.4M-184.6M-211.5M-2.00K
Earnings per share, basic-0.87-1.32-2.09-2.38-1.34-2.63-1.83-7.31-0.00
Earnings per share, diluted-0.87-1.32-2.09-2.38-1.34-2.63-1.83-7.31

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents51.7M75.2M83.2M61.9M173.3M183.4M175.1M92.4M0
Short-term investments198.5M217.3M365.5M455.4M284.0M644.6M355.4M367.0M0
Receivables1.50M1.90M1.70M3.30M6.00M2.80M2.40M3.11M
Inventory-62.5M-62.5M-20.0M-207.0M-60.7M-262.0M
Current assets257.7M303.4M459.1M528.8M471.3M845.1M544.6M468.0M0
Property, plant and equipment72.8M86.1M99.5M112.8M123.0M118.8M56.4M8.60M
Total assets415.9M548.7M642.8M821.6M1.05B1.23B717.8M773.9M0
Accounts payable4.27M5.39M5.90M13.9M10.3M10.4M9.25M12.3M0
Current liabilities32.5M35.5M37.1M53.7M47.9M94.3M33.1M29.5M2.00K
Long-term debt34.5M
Total debt83.3M90.8M95.1M101.1M73.1M53.8M53.0M34.5M
Total liabilities123.4M126.5M130.6M154.7M125.6M148.2M88.8M70.7M2.00K
Shareholders' equity292.5M422.2M512.2M666.9M925.2M1.01B629.0M703.2M-2.00K
Shares outstanding229.4M212.2M168.6M144.4M142.6M140.5M124.3M121.5M44.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-149.2M-200.3M-237.7M-220.5M-184.8M-115.1M-137.3M-44.7M-44.7M
Capital spending-386.0K-694.0K-1.52M-5.19M-21.4M-66.0M-50.8M-3.23M-5.33M
Free cash flow-149.6M-201.0M-239.2M-225.7M-206.3M-181.1M-188.1M-47.9M-50.0M
Cash from investing95.6M75.7M163.3M106.2M163.7M-505.1M164.1M-632.8M-632.8M
Cash from financing30.2M116.7M95.7M2.95M12.0M633.6M59.0M771.2M771.2M
Share buybacks895.0K1.53M2.46M2.46M3.62M2.84M1.78M654.3M
Change in cash-23.5M-7.94M21.3M-111.4M-9.19M13.4M85.7M93.7M93.7M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipOct 23, 2026Insider tradeSEC
144 · Notice of proposed saleOct 21, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 30, 2026Big-stake noticeSEC
8-K · Current reportSep 2, 2026Management or board changeSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 21, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
S-3 · Registration statementAug 12, 2026Offer documentSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
8-K · Current reportJun 22, 2026Meeting outcomeSEC
424B5 · ProspectusJun 22, 2026Offer documentSEC
DEFA14A · Additional proxy materialMay 28, 2026Meeting noticeSEC
8-K · Current reportMay 28, 2026Management or board changeSEC
DEFA14A · Additional proxy materialMay 20, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 23, 2026Big-stake noticeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
144 · Notice of proposed saleApr 21, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementApr 20, 2026Meeting noticeSEC
8-K · Current reportApr 15, 2026Current reportSEC
424B5 · ProspectusApr 15, 2026Offer documentSEC
424B5 · ProspectusApr 13, 2026Offer documentSEC
8-K · Current reportApr 13, 2026Current reportSEC
8-K · Current reportApr 13, 2026Current reportSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
144 · Notice of proposed saleJan 21, 2026Other filingsSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 23, 2025Insider tradeSEC
144 · Notice of proposed saleOct 21, 2025Other filingsSEC
8-K · Current reportOct 10, 2025Current reportSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 8, 2025Big-stake noticeSEC
8-K · Current reportAug 1, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
8-K · Current reportJun 23, 2025Meeting outcomeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
144 · Notice of proposed saleJun 10, 2025Other filingsSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeMay 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 23, 2025Insider tradeSEC
144 · Notice of proposed saleApr 21, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
144 · Notice of proposed saleMar 14, 2025Other filingsSEC
144 · Notice of proposed saleMar 14, 2025Other filingsSEC
S-8 · Registration statement for employee plansMar 13, 2025Offer documentSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 7, 2025Big-stake noticeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 4, 2025Insider tradeSEC
8-K · Current reportFeb 25, 2025Material contractSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
8-K · Current reportJan 29, 2025Management or board changeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
144 · Notice of proposed saleJan 21, 2025Other filingsSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 9, 2024Insider tradeSEC
144 · Notice of proposed saleDec 9, 2024Other filingsSEC
144/A · Notice of proposed sale, amendedDec 4, 2024Other filingsSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
8-K · Current reportNov 13, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G · Big-stake noticeNov 4, 2024Big-stake noticeSEC
4 · Change in ownershipOct 23, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedOct 22, 2024Big-stake noticeSEC
144 · Notice of proposed saleOct 21, 2024Other filingsSEC
8-K · Current reportOct 7, 2024Current reportSEC
4 · Change in ownershipAug 23, 2024Insider tradeSEC
144 · Notice of proposed saleAug 21, 2024Other filingsSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportAug 7, 2024ResultsSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
144 · Notice of proposed saleJun 18, 2024Other filingsSEC
3 · Initial statement of ownershipJun 11, 2024Insider tradeSEC
8-K · Current reportJun 10, 2024Management or board changeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
8-K · Current reportMay 31, 2024Material contractSEC
144 · Notice of proposed saleMay 29, 2024Other filingsSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
8-K · Current reportMay 14, 2024Current reportSEC
424B5 · ProspectusMay 14, 2024Offer documentSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveApr 26, 2024Other filingsSEC
4 · Change in ownershipApr 24, 2024Insider tradeSEC
CORRESP · Letter to the SECApr 23, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 23, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
144 · Notice of proposed saleApr 22, 2024Other filingsSEC
UPLOAD · Letter from the SECMar 19, 2024Other filingsSEC

This page holds 200 of 588 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Allogene Therapeutics, Inc.’s releases · as of Nov 3, 2026

Common shares
346,467,307
Fully diluted
346,467,307

Fully diluted

LineSharesAs of
Common shares346,467,307Nov 3, 2026

Share count over time

CountShares
Nov 3, 2026346,467,307

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock30.9M8.9%US$49.5MSep 30, 2026
Citadel24.6M7.1%US$39.3MSep 30, 2026
Frazier Life Sciences Management, L.P.22.4M6.5%US$35.9MSep 30, 2026
Pfizer Inc22M6.4%US$36.4MSep 30, 2026
Vanguard17.9M5.2%US$28.6MSep 30, 2026
State Street16.3M4.7%US$26.1MSep 30, 2026
Primecap Management Co13.1M3.8%US$21MSep 30, 2026
UBS10.7M3.1%US$17.1MSep 30, 2026
Fidelity10.6M3.1%US$17MSep 30, 2026
Sio Capital Management, LLC9.1M2.6%US$14.6MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Two Sigma9.09M2.6%US$14.5MSep 30, 2026
Marshall Wace, LLP7.97M2.3%US$12.8MSep 30, 2026
Geode Capital6.45M1.9%US$10.3MSep 30, 2026
Candriam S.C.A.5.42M1.6%US$8.71MSep 30, 2026
Goldman Sachs5.33M1.5%US$8.53MSep 30, 2026
GordonMD Global Investments LP5.3M1.5%US$8.48MSep 30, 2026
abrdn5.26M1.5%US$8.42MSep 30, 2026
Renaissance Technologies5.23M1.5%US$8.37MSep 30, 2026
Millennium5.12M1.5%US$8.18MSep 30, 2026
Patient Square Capital LP4.55M1.3%US$7.28MSep 30, 2026
D. E. Shaw & Co., Inc.4.26M1.2%US$6.82MSep 30, 2026
Hrt Financial LP3.35M0.97%US$5.35MSep 30, 2026
Morgan Stanley3.33M0.96%US$5.32MSep 30, 2026
Rtw Investments, LP3.25M0.94%US$5.2MSep 30, 2026
Dimensional3.2M0.92%US$5.12MSep 30, 2026
Wildcat Capital Management, LLC2.92M0.84%US$4.67MSep 30, 2026
Woodline Partners LP2.81M0.81%US$4.5MSep 30, 2026
Northern Trust2.81M0.81%US$4.49MSep 30, 2026
Ameriprise2.61M0.75%US$4.18MSep 30, 2026
Schwab2.37M0.68%US$3.79MSep 30, 2026
Acadian Asset Management LLC2.22M0.64%US$3.56MSep 30, 2026
Walleye Capital LLC2.21M0.64%US$3.53MSep 30, 2026
Bank of America2.01M0.58%US$3.21MSep 30, 2026
DAFNA Capital Management LLC2M0.58%US$3.2MSep 30, 2026
Boxer Capital Management, LLC1.5M0.43%US$2.4MSep 30, 2026
T. Rowe Price1.48M0.43%US$2.38MSep 30, 2026
JPMorgan1.42M0.41%US$2.3MSep 30, 2026
Qube Research & Technologies Ltd1.18M0.34%US$1.89MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.1.12M0.32%US$1.79MSep 30, 2026
Raiffeisen Bank International AG1.1M0.32%US$1.78MSep 30, 2026
Hennion & Walsh Asset Management, Inc.1.04M0.30%US$1.66MSep 30, 2026
Ghisallo Capital Management LLC1M0.29%US$1.6MSep 30, 2026
Invesco844K0.24%US$1.35MSep 30, 2026
BNY750K0.22%US$1.2MSep 30, 2026
Raymond James Financial Inc653K0.19%US$1.04MSep 30, 2026
Nuveen628K0.18%US$1MSep 30, 2026
MUFG546K0.16%US$874KSep 30, 2026
Gsa Capital Partners LLP543K0.16%US$868KSep 30, 2026
Man Group plc519K0.15%US$830KSep 30, 2026
Franklin Templeton483K0.14%US$575KSep 30, 2026

This page holds 50 of 192 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF12.1M3.5%US$25.3MJun 30, 2026
Select Biotechnology Portfolio9.55M2.8%US$20.7MMay 31, 2026
Vanguard Capital Opportunity Fund9.39M2.7%US$19.5MJun 30, 2026
Vanguard Total Stock Market Index Fund8.67M2.5%US$18MJun 30, 2026
iShares Russell 2000 ETF6.92M2.0%US$14.4MJun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund3.48M1.0%US$6.53MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.3.44M0.99%US$7.16MJun 30, 2026
Vanguard Extended Market Index Fund3.22M0.93%US$6.71MJun 30, 2026
Fidelity Small Cap Index Fund2.91M0.84%US$5.47MJul 31, 2026
iShares Russell 2000 Value ETF2.48M0.72%US$5.16MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Biotechnology ETF1.8M0.52%US$3.75MJun 30, 2026
Columbia Small Cap Value Discovery Fund1.8M0.52%US$3.38MJul 31, 2026
BlackRock Advantage Small Cap Core Fund1.44M0.42%US$3.13MMay 29, 2026
Fidelity Enhanced Small Cap Core ETF1.44M0.42%US$2.99MJun 30, 2026
Fidelity Extended Market Index Fund1.32M0.38%US$2.86MMay 31, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF1.31M0.38%US$2.73MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio1.21M0.35%US$2.62MMay 29, 2026
Schwab U.S. Small-Cap ETF1.21M0.35%US$2.62MMay 31, 2026
Vanguard Strategic Small-Cap Equity Fund1.16M0.33%US$2.41MJun 30, 2026
Dimensional U.S. Small Cap ETF1.03M0.30%US$1.93MJul 31, 2026
Vanguard Russell 2000 Index Fund799K0.23%US$1.73MMay 31, 2026
Vanguard Health Care Index Fund744K0.21%US$1.61MMay 31, 2026
U.S. Small Cap Portfolio666K0.19%US$1.25MJul 31, 2026
U.S. Micro Cap Portfolio665K0.19%US$1.25MJul 31, 2026
Schwab Small-Cap Index Fund645K0.19%US$1.21MJul 31, 2026
Small Cap Value Fund631K0.18%US$1.31MJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF589K0.17%US$1.11MJul 31, 2026
Vanguard U.S. Momentum Factor ETF497K0.14%US$1.08MMay 31, 2026
Master Small Cap Index Series496K0.14%US$1.03MJun 30, 2026
Fidelity Total Market Index Fund477K0.14%US$1.03MMay 31, 2026
iShares U.S. Small-Cap Equity Factor ETF476K0.14%US$896KJul 31, 2026
Multi-Manager Small Cap Equity Strategies Fund469K0.14%US$1.02MMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares413K0.12%US$776KJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account408K0.12%US$849KJun 30, 2026
Fidelity Series Total Market Index Fund387K0.11%US$839KMay 31, 2026
Fidelity Small Cap Value Index Fund372K0.11%US$774KJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF354K0.10%US$736KJun 30, 2026
Nuveen Small Cap Blend Index Fund353K0.10%US$663KJul 31, 2026
NVIT Multi-Manager Small Company Fund304K0.09%US$633KJun 30, 2026
JPMorgan Small Cap Value Fund295K0.09%US$614KJun 30, 2026
EQ/2000 Managed Volatility Portfolio289K0.08%US$600KJun 30, 2026
NVIT Small Cap Value Fund278K0.08%US$578KJun 30, 2026
Ultra-Small Company Market Fund250K0.07%US$520KJun 30, 2026
T. Rowe Price Health Sciences Portfolio243K0.07%US$506KJun 30, 2026
Dimensional U.S. Core Equity 2 ETF241K0.07%US$454KJul 31, 2026
Nuveen Equity Index Fund220K0.06%US$413KJul 31, 2026
Avantis U.S. Small Cap Equity ETF204K0.06%US$443KMay 31, 2026
LVIP State Street Small-Cap Index Fund191K0.06%US$397KJun 30, 2026
Small Cap Equity Fund183K0.05%US$381KJun 30, 2026
Fidelity Nasdaq Composite Index Fund168K0.05%US$364KMay 31, 2026

This page holds 50 of 157 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Parker Geoffrey M.
Officer: CHIEF FINANCIAL OFFICER
Sale36,342USD 1.34US$48,698Oct 21, 2026
Douglas Earl Martin
Officer: SVP, General Counsel
Sale29,697USD 2.12US$62,958Aug 21, 2026
Yoshiyama Annie
Officer: SVP, Finance
Sale9,586USD 2.31US$22,144Apr 21, 2026
Beneski Benjamin Machinas
Officer: SVP, Chief Technical Officer
Sale2,867USD 2.50US$7,168Mar 31, 2026

Big stakes

StakeStakeSharesDateFiling
Pfizer Inc9.00%22MNov 6, 2025Schedule 13D
Kenneth Griffin7.10%24.7MSep 30, 2026Schedule 13G
BlackRock, Inc.6.70%23.2MSep 30, 2026Schedule 13G
Frazier Life Sciences Public Fund, L.P.5.60%19.4MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Vicki Sato
Other companies: Vir Biotechnology, Inc. (Director · Since at least Oct 10, 2019); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jan 2, 2025 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 11, 2019 · Past); BorgWarner Inc. (Director · Feb 12, 2014 – Apr 29, 2020 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2007 – Jun 2, 2010 · Past); Bristol-Myers Squibb Company (Director · Jul 11, 2006 – Feb 1, 2021 · Past); Revvity, Inc. (Director · May 2, 2006 – Feb 9, 2017 · Past)
Director · Since at least Jul 30, 2021
Timothy L Moore
Other companies: BioLife Solutions, Inc. (Director · Since at least Sep 1, 2022); Cerus Corporation (Director · Since at least Sep 5, 2018); Instil Bio, Inc. (Chief Operating Officer · Sep 6, 2022 – Sep 6, 2022 · Past); Kite Pharma Inc (EVP, Technical Operations · Mar 15, 2016 – Oct 3, 2017 · Past)
Chief Technical Officer · Apr 24, 2023 – Feb 3, 2025 · Past
Arie Belldegrun
Other companies: UroGen Pharma Ltd. (Director · Since at least Mar 24, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020); Ginkgo Bioworks Holdings, Inc. (Director · Sep 16, 2021 – Jun 12, 2024 · Past)
Director · Since at least Mar 26, 2021
Elizabeth A Barrett
Other companies: Sage Therapeutics Inc (Director · Since at least Jun 11, 2025); UroGen Pharma Ltd. (Chief Executive Officer · Since at least Jan 3, 2019); LifeSci Acquisition II Corp (Director · Nov 20, 2020 – Nov 20, 2020 · Past)
Director · Since at least Jul 30, 2021
Rafael G. Amado
Other companies: Zai Lab Ltd. (President, Head of Global Research and Development · Since at least Dec 30, 2022); Poseida Therapeutics Inc (Director · Apr 13, 2023 – Jan 8, 2025 · Past); Adaptimmune Therapeutics PLC (President, R&D · Jan 1, 2016 – Aug 6, 2019 · Past)
EVP of R&D · Sep 3, 2019 – Oct 7, 2022 · Past
Deborah M Messemer
Other companies: TPG Inc. (Director · Since at least Jan 13, 2022); PayPal Holdings, Inc. (Director · Since at least May 26, 2021)
Director · Since at least Jun 10, 2021
Eric Thomas Schmidt
Other companies: Revolution Medicines, Inc. (Director · Jun 17, 2020 – Jun 8, 2023 · Past); Relmada Therapeutics, Inc. (Director · Dec 19, 2019 – May 25, 2023 · Past)
Chief Financial Officer · Oct 10, 2018 – Mar 22, 2023 · Past
Geoffrey Parker
Other companies: Perrigo Company plc (Director · Since at least May 14, 2024); Better Therapeutics, Inc. (Director · Dec 18, 2023 – Dec 18, 2023 · Past)
CHIEF FINANCIAL OFFICER · Since at least Oct 16, 2023
Stephen L. Mayo
Other companies: Sarepta Therapeutics, Inc. (Director · Since at least Nov 16, 2021); Merck & Company, Inc. (Board Member · Since at least Mar 15, 2021)
Bren Professor of Biology and Chemistry and Merkin Institute Professor · Since at least Jul 8, 2022
David Chang
Other companies: Kite Pharma Inc (EVP, R&D, Chief Medical Off. · Jun 19, 2014 – Oct 3, 2017 · Past)
Co-Founder · Since at least Oct 10, 2018
All 26 people
PersonSeat
Earl Douglas
Other companies: Biomimetic Therapeutics Inc (General Counsel · May 10, 2006 – Mar 26, 2012 · Past)
General Counsel · Since at least Aug 14, 2023
Liz Barrett
Other companies: UroGen Pharma Ltd. (President and Chief Executive Officer · Since at least Nov 4, 2026)
President and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology · Since at least Nov 6, 2026
Allogene Media/Investor Contact:Christine CassianoEVPChief Corporate Affairs & Brand Strategy · Since at least Apr 16, 2026
Annie YoshiyamaSenior Vice President, Finance and Corporate Controller, and Principal Accounting Officer · Since at least Apr 23, 2026
Benjamin M. BeneskiSenior Vice President, Chief Technical Officer · Since at least Jan 29, 2025
Christine CassianoExecutive Vice President, Chief Corporate Affairs and Brand Strategy Officer · Since at least Nov 3, 2026
Franz B. HumerDirector · Since at least Jun 18, 2025
Joshua KazamCo-Founder and Director · Since at least Jun 23, 2026
Leslie BryantExecutive Director, Corporate Communications · Since at least Nov 3, 2026
Lillian SmithVP, Corporate Counsel · Apr 1, 2023 – Apr 1, 2023 · Past
Owen WitteProfessor of Microbiology, Immunology and Molecular Genetics · Since at least Nov 6, 2026
Rocio ManghaniVice President, Market Access, Evidence & Strategy · Since at least Nov 5, 2026
Susie LundeenChief People Officer · Since at least Nov 6, 2026
Veer BhavnagriGeneral Counsel · Apr 16, 2020 – Mar 14, 2023 · Past
Yinlin Jack ChenSVP, Finance · Aug 10, 2023 – Aug 10, 2023 · Past
Zachary RobertsPresident and Chief Executive Officer · Since at least Nov 3, 2026

Open People

Log in to ask 6ix AI your own questions about Allogene Therapeutics, Inc.